FDA Approves Second Fly Species for Maggot Therapy
The FDA has approved Lucilia cuprina for maggot-based wound treatment, granting Cuprina Holdings exclusive access to the biosurgery market.
The U.S. Food and Drug Administration (FDA) has officially approved the use of Lucilia cuprina (Australian sheep blowfly) larvae for wound treatment, as announced by Singapore-based Cuprina Holdings on June 17. The company already holds FDA approval for Lucilia sericata (common green bottle fly) since 2004, making it the only company capable of selling two types of fly larvae for medical use.
Monopoly in the Biosurgery Market
Cuprina Holdings markets Lucilia cuprina larvae under the product name “MediFly Maggots.” In a statement, the company’s CEO David Quek said, “We are the sole holders of FDA approval for both fly species used in maggot wound therapy (MDT), a unique position no other company can claim. This establishes a wound care platform in one of the world’s most tightly regulated markets, providing defensive advantages for portfolio expansion.”
The company asserts that there is no significant difference in therapeutic efficacy between the two species. However, they emphasize the importance of market segmentation. While Lucilia sericata is widely recognized in Western wound care practices, Lucilia cuprina is better known in regions such as Australia, Africa, Asia, and parts of the Americas, opening up opportunities for geographical expansion.
Ronald Sherman, Cuprina’s Medical and Scientific Director, has been a long-time advocate of maggot therapy. He remarked, “Maggot wound therapy has firmly established itself in modern wound care, and the addition of a second FDA-approved species provides clinicians and patients with greater flexibility in treatment choices.”
Principles and Challenges of Maggot Therapy
Maggot Debridement Therapy (MDT) involves applying sterilized fly larvae to wounds to remove necrotic tissue. The larvae exclusively consume decayed tissue, leaving healthy tissue unharmed. Although this principle has been known for centuries, its adoption in modern medicine remains limited.
The biggest obstacle is the “repulsion factor.” Psychological resistance from patients and medical professionals poses a challenge, prompting some advocates to rebrand larvae with endearing nicknames like “cute baby flies,” “tiny walruses,” or “Maggie.” Another source of negative perception is the New World screwworm, an invasive species in the U.S. whose larvae feed on live tissue, causing severe damage to livestock. However, the Lucilia species used in MDT are non-parasitic and feed solely on necrotic tissue.
Cuprina Holdings expects FDA approval to improve accessibility to maggot therapy. Studies have reported its effectiveness as a minimally invasive alternative to surgical debridement for chronic wounds such as diabetic ulcers and bedsores. However, large-scale randomized controlled trials are lacking, highlighting the need for further evidence.
Regulatory Implications
It has been 22 years since the FDA approved Lucilia sericata in 2004, marking the second FDA-approved medical maggot species. During this period, no new regulatory frameworks for MDT have been established in the U.S., making Cuprina Holdings’ clearance an extension of existing regulations.
Cuprina Holdings aims to dominate the global maggot market. The company’s business model relies on a vertically integrated system of cultivation, sterilization, and shipping, ensuring strict quality control and leveraging FDA approval to establish barriers to market entry. The firm is also likely to seek regulatory approvals in emerging markets in the future.
While MDT is a low-cost and simple treatment method, only a limited number of products have passed regulatory approval processes. This latest approval is expected to accelerate the industrialization of the biosurgery sector.
Editorial Opinion
In the short term, Cuprina Holdings has gained a clear competitive edge in the U.S. market by offering two FDA-approved products. Medical facilities now have more opportunities to consider maggot therapy as an alternative to traditional surgical methods for necrotic tissue removal. As the number of patients with conditions such as diabetic ulcers and bedsores continues to rise, demand for minimally invasive and cost-effective treatments is likely to grow. However, psychological barriers to acceptance remain high, necessitating continued educational initiatives and clinical data collection.
In the long term, maggot therapy could potentially become a standard option in wound care. With an aging population and an increase in chronic wounds, coupled with the growing problem of antibiotic-resistant bacteria, interest in biologically based treatments is expected to persist. If Cuprina Holdings secures approvals in emerging markets, the global biosurgery market may expand significantly. However, it is also worth noting that the emergence of new mechanisms or synthetic alternatives could shift the role of maggot therapy in wound care in the future.
What remains to be seen is how flexible the FDA will be in regulating this type of biological treatment—a critical point to monitor for the industry’s evolution.
References
- Ars Technica — Published on 2026-06-17
Frequently Asked Questions
- For which types of wounds is maggot therapy used?
- Maggot therapy is primarily applied to chronic wounds requiring surgical debridement, such as diabetic ulcers, bedsores (pressure ulcers), and venous leg ulcers. Sterilized larvae exclusively dissolve and consume necrotic tissue without harming healthy tissue. They also secrete substances that promote wound healing.
- What are the differences between Lucilia cuprina and the previously approved Lucilia sericata?
- There is no significant difference in therapeutic effectiveness between the two species. The main distinction lies in geographic recognition: Lucilia cuprina is more familiar in regions such as Australia, Asia, and Africa, facilitating product expansion based on local medical practices.
- Are there safety concerns regarding maggot therapy?
- Only larvae cultured under sterile conditions for medical use are utilized, and they are non-parasitic, consuming only necrotic tissue without affecting live tissue. In the U.S., the FDA regulates these medical devices, ensuring rigorous control over the production process. They are distinctly different from parasitic species that feed on living tissue.
Comments